A variety of microparticles have been proposed for the sustained and localized delivery of drugs whit the objective of increasing therapeutic indexes by circumventing filtering organs and biological barriers. Yet, the geometrical, mechanical and therapeutic properties of such microparticles cannot be simultaneously and independently tailored during the fabrication process in order to optimize their performance. In this work, a top-down approach is employed to realize micron-sized polymeric particles, called microPlates (PLs), for the sustained release of therapeutic agents. PLs are square hydrogel particles, with an edge length of 20 m and a height of 5 m, made out of poly(lactic-co-glycolic acid) (PLGA). During the synthesis process, the PL Young's modulus can be varied from 0.6 to 5 MPa by changing PLGA amounts from 1 to 7.5 mg, without affecting the PL geometry. Within the porous PL matrix, different classes of therapeutic payloads can be incorporated including molecular agents, such as the anti-inflammatory dexamethasone (DEX), and nanoparticles, containing themselves imaging and therapeutic molecules. As a proof of principle, PLs are loaded with free DEX and 200 nm spherical polymeric nanoparticles, carrying DEX molecules (DEX-SPNs). Electron and fluorescent confocal microscopy analyses document the uniform distribution and stability of molecular and nano-agents within the PL matrice. This multiscale, hierarchical microparticle releases DEX for at least 10 days. The inclusion of DEX-SPNs serves to minimize the initial burst release and modulate the diffusion of DEX molecules out of the PL matrix. The pharmacological and therapeutic properties together with the fine tuning of geometry and mechanical stiffness make PLs a unique polymeric depot for the potential treatment of cancer, cardiovascular and chronic, inflammatory diseases.
INTRODUCTION
The systemic administration of nanoparticles for the detection and treatment of diseased tissues is progressively shaping up as a successful strategy, as demonstrated by the growing number of clinical trials based on nanomedicines. 1 The biophysical mechanisms regulating the accumulation of blood-borne nanoparticles within malignant tissues are mostly associated with the tortuosity and hyper-permeability of the diseased microcirculation, as compared to normal vascular beds. [2] [3] For the same mechanisms, a portion of intravenously injected nanoparticles tends also to accumulate within filtering organs, such as the liver and spleen, which are characterized by discontinuous and permeable vascular walls. 4 A variety of approaches have been proposed to reduce the unspecific deposition of nanomedicines within these filtering organs, including the proper tailoring of the nanoparticle surface, geometrical and mechanical properties. [5] [6] [7] An alternative approach relies on drug depots, which follow a different strategy. These are realized by the intra-tissue deposition of nano-and micro-particles, nanofibers and gels, and allow for the sustained and long-term release of large amounts of therapeutic agents. Importantly, these agents are directly deployed from the depot within the diseased tissue bypassing filtering organs and biological barriers, such as the blood brain, the intestinal and lung epithelial barriers. 8 As such, drug depots could represent a valuable alternative to the systemic administration of therapeutics in a number of applications. This has been already shown clinically and pre-clinically for cancer, cardiovascular, and localized, chronic inflammatory diseases. [9] [10] [11] In the post-surgical treatment of brain cancers, the local delivery of carmustine from biodegradable polymeric wafers is commonly practiced in the clinic and has contributed to improve the life expectation of patients diagnosed with high grade gliomas. 9, 12 In this application, polymeric wafers are deposited on the surface of the tumor's resected cavity and release their cytotoxic content for about 6 days with the objective of removing residual cancer cells. A similar strategy has been proposed for the treatment of other deadly malignancies, including pancreatic, liver and lung carcinomas. [13] [14] [15] Drug depots have been also developed for the management of cardiovascular diseases, chronic inflammatory diseases, and brain disorders. For instance, drug-coated balloons and medicated stents are used for modulating the risk of restenosis in atherosclerosis. [16] [17] After recanalization, thin films of cytotoxic agents are deposited onto the injured vasculature with the objective of inhibiting local cell growth and the risk of de novo occlusions. In osteoarthritis, nano and microparticles of chitosan and other polymers have been loaded with a variety of agents, including anti-inflammatory molecules, analgesics, growth factors, and injected intra-articularly to induce tissue repair and resolve local inflammation. [18] [19] The UV detection was set at 240 nm. The retention time of DEX was 3.65 min. An external standard curve in a linear concentration ranging from 1 to 300 μg/ml was used for the quantification of DEX. A standard solution (10 mg/ml in acetonitrile) was used for the construction of the standard curve. The amount of DEX was determined using the following equation (r2= 0.9997):
where x is the drug concentration (μg/ml). HPLC analysis showed that no interference was determined by the various components of MicroPlates.
LE and EE are determined using the following equations: Absorbance is measured at 570 nm, using 650 nm as reference wavelength (Tecan, Männedorf, Swiss). The percentage of cell viability is assessed according to the following equation:
where AbsT is the absorbance of treated cells and AbsC the absorbance of control (untreated) cells.
To investigate the anti-inflammatory activity of DEX-μPLs towards stimulated macrophages, the expression levels of three pro-inflammatory cytokines, namely TNF-α, IL-1β, and IL-6, are The maximum force applied to the sample is 1 nN.
Preparation of Spherical Polymeric Nanoparticles (SPNs). Spherical polymeric nanoparticles
are prepared by a slightly modified oil-in-water (O/W) emulsion/solvent evaporation technique, as compared to previous work of the authors and other scientists. [31] [32] Briefly, 300 µl of DEX solution (6.66 mg/ml, in acetone) is added at 450 µl of organic solution containing PLGA (1 mg, in chloroform), DPPC (100 g in chloroform) and mixed using a probe sonicator for 15 sec at 60%
Amplitude. This mixture is added drop by drop into 3 ml of 4% ethanol containing 110 g of DSPE-PEG-COOH and sonicated for 1 min at 60% Amplitude. The resulting emulsion is placed under reduced pressure and magnetic stirring to foster the evaporation of the organic solvents.
After the complete removal of organic solvents, the obtained nanoparticles are purified through centrifugation. To remove the debris of the synthesis procedure, at first the solution is centrifuged at 452 g for 2 min, and then SPNs undergo several centrifugations at 18,213 g for 15 min to remove the unloaded drug. In order to demonstrate SPNs integrity after loading into μPLs, DEX is replaced with gold nanoparticles, and part of DSPE-PEG is substituted with DSPE-Cy5. Preparation and characterization of SPNs-loaded MicroPlates. DEX-SPNs-μPLs are synthesized using the protocol used for DEX-μPLs fabrication, with some modifications. To prevent DEX-SPNs damaging during the synthesis process, they are added to a 20% (w/v) PVA aqueous solution, under magnetic stirring, for 15 min, in order to get a PVA coating. Subsequently, PVA coated DEX-SPNs are purified using centrifugation and finally added to the polymeric mixture (5 mg of PLGA) and spread onto the PVA template. Then DEX-SPNs-µPLs are released, purified, and characterized as above reported for DEX-µPLs.
Characterization of DEX-loaded
To assess their distribution and their integrity after the loading process into µPLs, gold nanoparticles-loaded Cy5-tagged-SPNs (Au-Cy5-SPNs) are loaded into CURC-µPLs and then analyzed using Nikon A1 confocal microscopy (Dexter, MI) and a JEOL JEM 1011TEM , operating with an acceleration voltage of 100 kV and equipped with a 11 Mp fiber optical charge coupled device (CCD) camera (GATAN Orius 830). For TEM analysis, µPLs from a suspension are dried onto glass slide and embedded into Lowicryl ® K11M resin. The resin is polymerized for 48h under UV lamp (wavelength 365 nm) and then cut using LEICA EM UC6 ultra-microtome and ultra sonic 35° DIATOME diamond knife. Curcumin for its intrinsic fluorescence was used for microscopy analysis. Curcumin-loaded µPLs (CURC-µPLs) were obtained by depositing a paste of poly(lactic-co-glycolic acid) (PLGA) and curcumin within the sacrificial PVA template. MicroPlates were characterized using different techniques ( Figure. 2). In particular, a scanning electron microscopy (SEM) image is reported in Figure. 2A, showing the specific geometry of μPLs: a square shape with edge length of about 20
μm and a height of about 5 μm, which precisely fit the size and shape of the wells in the original master silicon template. A size distribution analysis via Multisizer showed a single peak of ~15 μm with a relatively narrow distribution (Figure.2B) . Indeed, given the non-spherical shape of the μPLs, the instrument returns an average characteristic size rather than the actual edge length of the particle. The µPL eletrostatic surface charge was of -17.9 ± 5.1 mV, which is due to the carboxylic termination on the PLGA chains. E CURC-µPLs on a human fibroblast monolayer.
Biopharmaceutical characterization of Dexamethasone-loaded MicroPlates. DEX was used as a 'model drug' in that it is one of the most commonly prescribed corticosteroid for the treatment of moderate to severe pains, fever and inflammation, which are symptoms quite common to many pathological conditions. 33 The three different configurations, namely 1, 5 and 7.5 mg PLGA, were characterized in terms of yielding, loading (LE) ( Figure.3A and B) , DEX amounts per μPL, and encapsulation efficiency (EE%) ( Figure.S2A and B) . For the yielding, which is defined as the percentage of released μPLs over the number of wells in the original silicon template, a similar number of μPL/template was generated in all the three configurations. This was about 6.5 × 10 suggest that overall the release profile is not strongly influenced by the pH, and thus by polymer degradation within the considered period, but it is mainly controlled by DEX diffusion out of the matrix. In fact, it is well known that PLGA particle degradation is an autocatalytic process which starts from the inside of the matrix. 35 In our experiments, the presence of an acidic microenvironment could mainly promote the surface erosion of the particles and facilitate the escape of the outer DEX molecules.
In order to verify this matrix biodegradation, µPLs loaded with the red fluorescent dye Rhodamine B (RhB-µPLs) were synthetized and characterized over time for possible morphological changes.
Figure.3E reports bright field, fluorescent and scanning electron microscopy images, taken at different time points, upon µPLs exposure to physiological and pathophysiological conditions. At day 1, RhB-µPLs appeared as square blocks in both cases, but starting from day 3 in acidic conditions, µPL merges appear less straight and, at day 10, µPLs structure appeared roundish and surrounded by spherical microparticles, possibly deriving from the self-assembly process of the eroded polymeric mass. All together these data prove that the degradation process of the particles became a relevant phenomenon only at longer time point, when a significant portion of the drug has been already released. Similarly, RAW 264.7 viability was not altered upon 24h incubation with free DEX or DEX-μPLs, even at the greatest tested concentration (30 μM). Note that 30 μM DEX is a concentration 3 times greater than the greatest concentration of DEX used for anti-inflammatory experiments. Also, the incubation time (24 h) was almost 3 times longer than the efficacy experiments, confirming that the DEX-μPLs can be efficiently used as a local drug delivery system. Based on these preliminary considerations, RAW 264.7 and primary bone marrow-derived macrophages (BMDMs) were incubated with DEX-µPL, at 1 µM and 10 µM DEX concentrations, and then stimulated with LPS to induce the secretion of TNF-α, IL-1β and IL-6. Data are presented in Figure. 4D for RAW 264.7 cells and Figure.4E for BMDMs. Data clearly show that DEX-µPLs drastically reduce the secretion of all three considered inflammatory cytokines, in a concentration dependent manner.
However, 1 µM of DEX-µPLs is already sufficient to decrease the expression of IL-1 and IL-6
by two and three orders of magnitude, respectively, in the case of BMDMs. Interestingly, the strongest inhibitory effect was registered for the primary macrophages (BMDMs) that appear also to be more extensively stimulated by LPS as compared to RAW 264.7 cells. 36 For instance, the stiffness value for 5 mg PLGA µPLs, which is of about 2.08 ± 0.5 MPa, is similar to the one of cartilage tissues. 37 Nevertheless, this modulation in mechanical properties, by changing PLGA amount, do not affect µPLs size and shape. As from SEM images, besides a very moderate increase in central concavity, there is no morphological difference among µPLs realized with 1, 5 and 7.5 mg of PLGA ( Figure. 5A-C, respectively).
The observed trend for the stiffness-PLGA amount relationship is in agreement with the well accepted notion that hydrogel stiffness can be modulated by changing polymer concentration. 38 Noteworthy, for polymeric nanoparticles obtained via a conventional bottom-up approach, an increase in polymer mass is generally associated with an increase in hydrodynamic diameter. 39 In other words, the proposed top-down approach allows us to control the geometry and the mechanical properties of the particles simultaneously and independently. DEX-SPNs were dispersed within the polymeric paste used for assembling the µPLs and deposited over the template following the same approach used for DEX-µPLs. However, prior to their dispersion in the paste, DEX-SPNs were protected by a thin PVA coating which did not alter their physicochemical properties (see Figure.S3 ). At this point, the release of dexamethasone acetate from DEX-SPNs, DEX-μPLs, and DEX-SPNs-μPLs was studied. A direct comparison is shown in Figure. 6B. For DEX-SPNs, about 90% of DEX was released within the first 8 h, whereas the remaining 10% was released within the following 48h. In the case of DEX-µPLs, only 60% of DEX was released during the first 8h, followed by a slow release until 10 days. Finally, the release from DEX-SPNs-μPLs was much slower: at 8h, only around 35% of DEX was released. This represents about 0.5 and 0.25 times the drug amounts released from DEX-SPNs and DEX-µPLs, respectively. This trend slower release is observed throughout the whole experiment (240 h). Based on fitting considerations, the three release data are statistically different (p value < 0.0001). The entrapment efficiency of DEX-SPNs inside µPLs slows down DEX release, probably for the presence of the polymer matrix surrounding DEX-SPNs. In this case, water has to first penetrate and hydrate the µPLs matrix, and, after that, reach and hydrate the SPNs, as to free the drug molecules and starts their diffusion within the two polymeric matrices. Furthermore, the presence of the PVA surfactant on SPNs could contribute to this effect. The use of SPNs as drug carriers and loading them inside the PLs represents a strategy for modulating the release, especially within the first h, and for realizing truly multifunctional systems.
To document the encapsulation and stability of SPNs within the µPL matrix, confocal fluorescent microscopy and transmission electron images were generated for SPNs loaded with gold nanoparticles and labeled with RhB ( Figure. 
CONCLUSION
Micron-sized polymeric particles -the PLs -were realized using a top-down fabrication approach that allows us to control precisely and independently their geometrical, mechanical and pharmacological properties. PLs have a square base with an edge length of 20 m and a height of 5 m. In previous works, using the same fabrication strategy, the authors have shown that particle geometry can be readily tailored. [26] [27] Furthermore, controlling the amount of PLGA allow us to realize PLs with different mechanical stiffness, without affecting the actual particle geometry. With a PLGA amount ranging from 1 to 7.5 mg, the PL Young's modulus changed by one order of magnitude, namely from 0.6 MPa up to 5 MPa. The particle deformability is crucial in facilitating their deposition and integration with the surrounding tissues.
In terms of pharmacological properties, the anti-inflammatory molecule Dexamethasone was dispersed within the PL matrix, and sustained release over a period of 10 days was demonstrated, with a significant burst within the first few h followed by a steady, continuous release. It was also
shown that PL could be loaded with nanoparticles whereby such a hierarchical system can be used for building, in a modular way, multiple functionalities in the PLs. Specifically, it was demonstrated that the release profile of DEX could be modulated by dispersing within the PL matrix spherical polymeric nanoconstructs, loaded themselves with DEX, thus diminishing the initial burst release and modulating release throughout the whole process.
Our findings evidence that µPLs can be used as a drug depot, combining sustained release profile, needed for all local drug delivery systems, with a precise control in geometrical and mechanical properties, fostering optimal tissue implantation. The latter are uniformly distributed within the green matrix of PLs
